ArticleCell death discovery2024

TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the ESR2-mediated MAPK pathway.

Ding-Guo Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.